KIT and nephrolithiasis: We had previously validated the utility of the biomarkers comprising the KIT Assay in chronic kidney disease [10], chronic lung transplant rejection [26,27], nephrolithiasis [11], and kidney transplant rejection [12,28], suggesting its utility across a range of diseases and chronicity states.